Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (DE:SFY)
FRANKFURT:SFY
Theriva Biologics (SFY) Stock Price & Analysis
4 Followers
SFY Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.34 - €1.28
Previous Close€0.4
Volume0.00
Average Volume (3M)500.00
Market Cap
€7.68M
Enterprise Value-€11.83M
Total Cash (Recent Filing)$23.18M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)N/A
Beta0.24
Next Earnings
May 08, 2024EPS Estimate
-€0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,148,049
10 Day Avg. Volume0
30 Day Avg. Volume500
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
€1.85Price Target Upside355.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Theriva Biologics News
PremiumCompany Announcements
Theriva Biologics’ VCN-01 Shows Promise in Pediatric Cancer Trial
PremiumCompany Announcements
Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy
PremiumCompany Announcements
Theriva Biologics Upcoming Investor Presentations InsightOptions Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.17% Other Institutional Investors
99.83% Public Companies and
Individual Investors
SFY FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was €0.34 and its highest was €1.28 in the past 12 months.
What is Theriva Biologics’s market cap?
Currently, no data Available
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is May 08, 2024 which is in 4 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Mar 25, 2024. The company reported -€0.288 earnings per share for the quarter, beating the consensus estimate of -€0.38 by €0.093.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -€0.18.
How many shares outstanding does Theriva Biologics have?
Currently, no data Available
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -€0.288 in its last earnings report, beating expectations of -€0.38. Following the earnings report the stock price went up 1.351%.
Which hedge fund is a major shareholder of Theriva Biologics?
Among the largest hedge funds holding Theriva Biologics’s share is Fisher Asset Management LLC. It holds Theriva Biologics’s shares valued at N/A.
---
Theriva Biologics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.85 (355.37% Upside)
€1.85 (355.37% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.17%
12-Months-Change
Fundamentals
Return on Equity
-38.93%
Trailing 12-Months
Asset Growth
-19.75%
Trailing 12-Months
Company Description
Theriva Biologics
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
---
SFY Earnings Call
Q4 2024
0:00 / 0:00
---
SFY Stock 12 Months Forecast
Average Price Target
€1.85
▲(355.37% Upside)
Technical Analysis
Best Analysts Covering SFY
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-32.12%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -32.12% per trade.
---